Immatics NV (IMTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN NL0015285941
Immatics NV financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 65.25 m USD |
| Gross profit | 65.25 m USD |
| Operating income | -205.93 m USD |
| EBIT | -247.02 m USD |
| Net income | -222.26 m USD |
| Diluted EPS – continuing operations | -2.12 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
More stocks
- Ningxia Western Venture Industrial Co Ltd (000557.SZ)
- HomeTrust Bancshares, Inc. (HTB)
- Solstad Offshore ASA (SOFF.OL)
- FRoSTA (NLM.F)
- Ottogi (007310.KS)
- CECEP Techand Ecology&Environment Co Ltd (300197.SZ)
- INDEPENDENT BANK CORP /MI/ (IBCP)
- Suzhou Keda Technology Co Ltd (603660.SS)
- China Water Affairs Group Ltd (855.HK)
- Hangzhou Star Shuaier Electric Appliance Co Ltd (002860.SZ)
- J.Pond Precision Technology Co. Ltd. A (301326.SZ)
- Zhejiang Fore Intelligent Technology Co. Ltd. A (301368.SZ)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.